Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextrothyroxine is the dextrorotary isomer of thyroxine and acts as a synthetic thyroid hormone. It was developed and marketed under the brand name Choloxin as an antihyperlipidemic agent for lowering high circulating cholesterol levels, particularly in hyperlipidemia. Its mechanism of action involves stimulating the formation and catabolism of low-density lipoprotein (LDL) in the liver, leading to increased excretion of cholesterol and bile acids via the biliary route. This results in reduced serum cholesterol and LDL levels without significantly affecting high-density lipoproteins (HDL). As a prohormone, dextrothyroxine also binds to thyroid hormone receptors (alpha and beta) as an agonist and serves as a substrate for iodide peroxidase. The drug was withdrawn from clinical use due to cardiac side effects[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextrothyroxine.